Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (GEHC) launched CareIntellect for Operations, an AI-enabled SaaS application that forecasts hospital capacity constraints up to 72 hours in advance across units, departments, and enterprises.
The software analyzes hundreds of patient and operational data points, including bed availability, staffing, wait times, and ancillary services, and recommends prescriptive actions to optimize capacity and throughput. It uses two proprietary AI models: a Pressure Forecast model that predicts emerging resource constraints and an Estimated Day of Discharge model that continuously updates discharge predictions and prioritizes workflows. The Queen’s Health Systems and Duke Health will be the first clinical evaluation sites, providing frontline feedback for future enhancements. CareIntellect for Operations runs on AWS, is available directly and via AWS Marketplace, and builds on more than two decades of operations expertise and Command Center deployments at nearly 500 facilities. Since 2023, GE HealthCare has invested over $5.1 billion in innovation supporting such offerings.
GE HealthCare (Nasdaq: GEHC) has received CE Mark for its Photonova Spectra photon-counting CT system, which uses proprietary Deep Silicon detector technology. This regulatory milestone allows clinical adoption and commercial activities in CE Mark–observing countries, following prior U.S. FDA 510(k) clearance and Japanese regulatory approval.
Photonova Spectra offers ultra-high definition imaging, on-demand spectral and spatial data for every scan, wide 80 mm detector coverage, and a 0.23‑second rotation speed. According to GE HealthCare, the system is designed to support neurology, oncology, musculoskeletal, thoracic and cardiac imaging, while managing up to 50x more data than conventional CT using NVIDIA’s accelerated computing platform.
GE HealthCare (Nasdaq: GEHC) introduced three new cardiovascular ultrasound systems — Vivid Explorer, Vivid Advanced and Vivid Focus — expanding its Vivid portfolio alongside the ultra-premium Vivid Pioneer and portable Vivid iq. The systems will be showcased at the ESC Congress 2026 in Munich.
The new platforms share the cSound software-based imaging architecture, AI-enabled workflow and a familiar Vivid user interface, and are tailored to settings from high-volume echo labs to everyday cardiac imaging. The latest EchoPAC Software Only v211 extends these capabilities to off-cart analysis. Vivid Explorer, Vivid Advanced, Vivid Focus and EchoPAC v211 have CE Mark and are 510(k) pending and not yet available for sale in the U.S.
GE HealthCare (Nasdaq: GEHC) announced that members of its management team will present at the Wells Fargo 21st Annual Health Conference/b) on at 10:15 a.m. ET / 9:15 a.m. CT. A live webcast will be accessible via the company’s investor relations events page.
GE HealthCare (Nasdaq: GEHC) has appointed William (Bill) Grogan as Chief Financial Officer, effective September 14, 2026. He succeeds Jay Saccaro, who previously stepped down for an expanded role outside medical technology. Interim CFO George Newcomb will continue as Controller and Chief Accounting Officer.
Grogan joins from Xylem, a water solutions company with about $9 billion in revenue, where he has served as executive vice president and CFO since 2023 and oversaw the integration of a $7.5 billion acquisition. He previously spent over a decade at IDEX, including six years as CFO, and earlier held finance roles at Walgreens, Crane Co., and Sears Holdings. He serves on the Board and Audit Committee of Crane NXT and holds an MBA from Northwestern’s Kellogg School of Management and a finance degree from Merrimack College.
GE HealthCare (NASDAQ: GEHC) introduced the new LOGIQ e family, comprising LOGIQ e Xi and LOGIQ e Si, laptop-sized ultrasound systems designed to deliver console-level imaging across multiple care settings. The systems target applications such as emergency medicine, critical care, musculoskeletal, rheumatology and anesthesiology.
According to GE HealthCare, LOGIQ e Xi is the premium model, adding AI-powered tools like Nerveblox and MSK Go, B-Flow blood flow imaging, Speckle Reduction Imaging-HD, Automated Function Imaging and SonoBiometry. Both systems can integrate Verisound cloud tools, and LOGIQ e Xi supports Vscan Air probe compatibility. The latest LOGIQ e systems are 510(k) cleared and CE Marked.
GE HealthCare (NASDAQ: GEHC) launched Invenia ABUS Prime, an automated 3D breast ultrasound system, and ABUS StreamVue, a zero-footprint browser-based reading solution recently cleared via U.S. FDA 510(k) and granted CE Marking, expanding its breast imaging portfolio for women with dense breasts.
Invenia ABUS Prime, which is among the first U.S. installations at BeSound in Los Angeles, is designed to standardize supplemental screening alongside mammography, support multi-site workflows, and enhance patient comfort. The system features the cSound Imageformer, Verisound AI tools, Fast Scan for up to 40% faster exams, a new Reverse Curve transducer, and selectable compression levels.
AI-supported reading via QVCAD is reported to cut reading time by 33% and reach up to 93% lesion-detection sensitivity. ABUS StreamVue, powered by Candelis and delivered in collaboration with Candelis, enables remote ABUS exam review, adaptable licensing, and simpler deployment across enterprise imaging networks.
According to GE HealthCare, Invenia ABUS Prime holds U.S. FDA Premarket Approval and CE Marking, while ABUS StreamVue is FDA 510(k) cleared and CE Marked, with availability dependent on local regulatory approvals.
GE HealthCare (Nasdaq: GEHC) reported second quarter 2026 revenues of $5.3 billion, up 5.7% year-over-year, with organic revenue growth* of 3.5%. Organic orders rose 11.1%, delivering a book-to-bill of 1.15x and a record backlog of $23.9 billion.
Net income attributable to GE HealthCare was $561 million (margin 10.6%) and Adjusted EBIT* was $750 million (margin 14.2%). Diluted EPS reached $1.24, up 16.5%, and Adjusted EPS* was $1.13, up 6.6%, both aided by IEEPA tariff refunds and a lower tax rate. Operating cash flow was $168 million and Free cash flow* $68 million.
Advanced Imaging Solutions and Pharmaceutical Diagnostics grew revenues 7.9% and 15.6%, respectively, while Patient Care Solutions revenues declined 13.3% with negative EBIT. The company repurchased 3.3 million shares for $200 million, declared a $0.035 dividend, and reaffirmed full-year 2026 guidance, including 3.0–4.0% organic revenue growth* and Adjusted EPS* of $4.80–$5.00.
GE HealthCare (Nasdaq: GEHC) announced that Chief Financial Officer Jay Saccaro will step down for an external role outside medical technology. George Newcomb, currently Controller and Chief Accounting Officer, has been appointed interim CFO. Saccaro will remain through August 14, 2026 to support a smooth transition while the company conducts a search for a permanent successor.
GE HealthCare also released preliminary, unaudited second quarter 2026 results. The company expects total revenues of $5.295 billion, up 5.7% year over year, and Organic revenue* of $5.182 billion, up 3.5%. The company expects year-over-year growth in diluted EPS and Adjusted EPS* above its prior expectation and reaffirmed full-year 2026 guidance issued on April 29, 2026. Complete Q2 results will be reported on July 29, 2026, followed by an earnings call at 8:30 am ET.
GE HealthCare (Nasdaq: GEHC) announced MIM Anyware, a web-based remote access platform that provides secure, healthcare system-controlled access to the full MIM software portfolio without local installation. Authorized users can review and process imaging data from virtually any location, supporting multidisciplinary collaboration and clinical decision-making across departments.
MIM Anyware enables multiple users such as physicians, physicists and dosimetrists to join the same session, perform clinical processing, deploy workflows and review registrations and dose in real time. According to GE HealthCare, this aims to streamline cross-functional collaboration, particularly in oncology workflows from consultations and referrals to tumor board discussions and education. The company also highlighted complementary MIM offerings, including MIM Maestro for reirradiation and composite dose assessment and MIM Contour ProtégéAI+ 2.0 with new MR Brain and updated CT Male Pelvis auto-contouring models, as part of a vendor-neutral software portfolio spanning multiple clinical specialties.